WXXWY WUXI BIOLGCS ADR
- 5.450
- +0.690+14.50%
WUXI BIOLGCS ADR News
Hong Kong Stocks End Week Higher as Tech Counters Rally
Biomedical sector showing strong performance, Pharmaron (03759) rose by 14.97%. Institutions believe there is still room for further increase in sector valuation.
Golden Finance News | The biomedical sector is showing strong performance, with Pharmaron (03759) up 14.97%, Remegen (09995) up 13.59%, Tigermed (03347) up 12.58%, Wuxi Bio (02269) up 11.79%, Wuxi Apptec (02359) up 10.56%, Akeso (09926) up 8.92%. In terms of news, Guoyuan International believes that the main reason for the outperformance of the pharmaceutical sector in this round of large gains is due to the deeper decline in the pharmaceutical sector in the previous period (as of September 23, MSCI China Meheco Group Index has fallen 23% year-to-date), sector.
HK stock abnormal movement | wuxi bio (02269) surged more than 16% in the afternoon, the company responded to rumors of selling business, institutions stated that selling business constitutes a positive catalyst.
wuxi bio (02269) rose more than 16% in the afternoon, as of the time of publication, up 12.33%, at 21.05 Hong Kong dollars, with a turnover of 19.34 billion Hong Kong dollars.
China's assets continue to be popular! Japan's listed 500ETF rose by 115%, while the Hang Seng Index in Hong Kong once approached its recent high point.
What news stimulated the rise of semiconductor and pharmaceutical stocks in the Hong Kong stock market? What is the reason for the strong performance of petroleum stocks?
[Brokerage Focus] Nomura: If the sale of the business is implemented, investors are expected to react more positively towards wuxi apptec compared to wuxi bio.
Kingwu Financial News | Nomura published a research report, according to the report on October 3rd, due to uncertainties related to the "Biosafety Law", wuxi apptec (02359) and wuxi bio (02269) are considering selling part of their business units. The report indicates that wuxi apptec has already put up for sale one of its business units (BU) the gene therapy CTDMO business, while also testing the market's interest in acquiring a production facility in Germany, which was acquired from Bayer in 2021. The bank calculates that wuxi bio's production facility in Germany accounts for 6% of the company's total capacity. The bank believes that if the aforementioned business sales are finalized, investors are expected to respond positively to wuxi bio.
Hong Kong stock market anomaly | CRO concept stocks lead the gains. The US Biological Safety Act is unlikely to be implemented this year, and medical investment and financing are expected to recover rapidly in the rate-cut cycle.
CRO concept stocks performed well in the morning trading session, as of the time of publication, Wuxi AppTec (02359) rose by 7.32% to HKD 64.55; Tigermed (03347) rose by 7.02% to HKD 51.05; Wuxi Bio (02269) rose by 6.72% to HKD 20; Pharmaron (03759) rose by 6.67% to HKD 16.96.
Express News | WuXi AppTec Put Its Cell and Gene Therapy Manufacturing Arm Wuxi Advanced Therapies, up for Sale - FT
Express News | China’s Wuxi Explores Sale of Pharma Units as US Restrictions Loom- FT
Trending Industry Today: PHARMARON Leads Losses In CRO Stocks
Trending Industry Today: TIGERMED Leads Gains In CRO Stocks
Market Chatter: Chinese Investors Buy More Hong Kong Stocks Ahead of National Day Break
[Hong Kong Stock Connect] Wuxi Bio (02269) rose by 8.14% as the earlier version of the US Biosafety Law was partially amended. Wuxi Bio was not included.
Kingwus Financial News | Wuxi Biologics (02269) oscillated stronger, as of press time, up 8.14%, at HK$17.28, with a turnover of 2.102 billion Hong Kong dollars. On the news front, on September 23, local time in the USA, Chairman of the Senate Committee on Homeland Security and Governmental Affairs, Gary Peters, submitted an amendment S.3558 to the Senate. The S.3558 bill, previously widely known as the Senate version of the 'Biological Safety Act,' had 11 votes in favor and 1 vote against at a hearing held by the Senate Committee on Homeland Security and Governmental Affairs in March this year.
Trending Industry Today: SUNAC Leads Gains In Top Gainers Yesterday Stocks
Trending Industry Today: WUXI BIO Leads Gains In Biotechnology Stocks
Trending Industry Today: WUXI APPTEC Leads Gains In Biotechnology Stocks
Trending Industry Today: WUXI BIO Leads Gains In CRO Stocks
HK stocks anomaly | CRO concept stocks continue to rise, hindered by the enactment of the Biosecurity Law, top companies' investment sentiment is expected to marginally improve.
The CRO concept stocks continue to rise. As of the time of publication, Tigermed (03347) rose by 9.28%, to 31.2 Hong Kong dollars; Pharmaron (03759) rose by 4.85%, to 11.24 Hong Kong dollars; and Joinn Laboratories (06127) rose by 4.8%, to 7.64 Hong Kong dollars.
wuxi bio spent 17.258 million Hong Kong dollars on September 25 to repurchase 1.326 million shares.
GLN September 25th, wuxi bio (02269.HK) announced that it spent 17.258 million Hong Kong dollars on September 25th to repurchase 1.326 million shares.
Another wave! The revised version of the "Biosecurity Act" introduced to the legislative agenda in the US Senate, but the suspense of "breaking through" still lingers.
①On the 23rd local time in the United States, the U.S. Senate will include Amendment S.3558 in the Senate legislative agenda by general order, confirming the new name of the bill, and there is unusual movement in the BrightGene system; ②Amendment S.3558 does not include the "grandfather clause" of the House version of the Biosecurity Act regarding exemptions, nor does it make any changes to the entities involved.
Hong Kong stocks surged by more than 7%, with wuxi bio (02269) soaring. Reports suggest that wuxi bio has been removed from the latest amendment to the US "Biological Safety Law".
Wuxi Bio(02269) surged more than 7%, as of the time of publication, up 7.47%, trading at 13.82 Hong Kong dollars, with a turnover of 1.682 billion Hong Kong dollars.
Analysis
Price Target
No Data
No Data
